Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Metformin + Sirolimus |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Metformin | Glucophage | Apo-Metformin | mTOR Inhibitor 51 | Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR and is FDA approved for type 2 diabetes (FDA.gov). |
Sirolimus | Rapamune | Rapamycin | mTORC1 Inhibitor 9 | Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02145559 | Phase I | Metformin + Sirolimus Sirolimus | A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02048384 | Phase Ib/II | Metformin + Sirolimus Metformin | A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | Completed | USA | 0 |